Serotonin: A New Hope in Alzheimer’s Disease?

Alzheimer’s disease (AD) is the most common form of dementia affecting 35 million individuals worldwide. Current AD treatments provide only brief symptomatic relief. It is therefore urgent to replace this symptomatic approach with a curative one. Increasing serotonin signaling as well as developing...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	ACS chemical neuroscience 2015-07, Vol.6 (7), p.940-943
Hauptverfasser:	Claeysen, Sylvie, Bockaert, Joël, Giannoni, Patrizia
Format:	Artikel
Sprache:	eng
Schlagworte:	Alzheimer Disease - drug therapy Alzheimer Disease - metabolism Alzheimer Disease - prevention & control Amyloid beta-Protein Precursor - metabolism Animals Clinical Trials as Topic Humans Life Sciences Neurobiology Neurons and Cognition Nootropic Agents - pharmacology Nootropic Agents - therapeutic use Receptors, Serotonin - metabolism Receptors, Serotonin, 5-HT4 - metabolism Serotonin - metabolism Serotonin 5-HT4 Receptor Agonists - pharmacology Serotonin 5-HT4 Receptor Agonists - therapeutic use Serotonin Antagonists - pharmacology Serotonin Antagonists - therapeutic use Serotonin Uptake Inhibitors - pharmacology Serotonin Uptake Inhibitors - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Alzheimer’s disease (AD) is the most common form of dementia affecting 35 million individuals worldwide. Current AD treatments provide only brief symptomatic relief. It is therefore urgent to replace this symptomatic approach with a curative one. Increasing serotonin signaling as well as developing molecules that enhance serotonin concentration in the synaptic cleft have been debated as possible therapeutic strategies to slow the progression of AD. In this Viewpoint, we discuss exciting new insights regarding the modulation of serotonin signaling for AD prevention and therapy.
ISSN:	1948-7193 1948-7193
DOI:	10.1021/acschemneuro.5b00135